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Abstract
There is an unmet need for accurate and practical screening to detect myocarditis. We sought to test the hypothesis that the extent
of acute myocarditis, measured by late gadolinium enhancement (LGE) on cardiac magnetic resonance imaging (CMR), can be
estimated based on routine blood markers. A total of 44 patients were diagnosed with acute myocarditis and included in this
study. There was strong correlation between myoglobin and LGE (rs = 0.73 [95% CI 0.51; 0.87], p < 0.001), while correlation
was weak between LGE and TnT-hs (rs = 0.37 [95% CI 0.09; 0.61], p = 0.01). Receiver operating curve (ROC) analysis deter-
mined myoglobin ≥ 87 μg/L as cutoff to identify myocarditis (92% sensitivity, 80% specificity). The data were reproduced in an
established model of coxsackievirus B3 myocarditis in mice (n = 26). These data suggest that myoglobin is an accurate marker of
acute myocarditis.
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LGE Late gadolinium enhancement
LVEF Left ventricular ejection fraction
NT-pro BNP NT-pro brain natriuretic peptide
PVC Premature ventricular contractions
rs Spearman rank correlation coefficient
SD standard deviation
Tc Thrombocytes
TnT-hs High sensitivity troponin T
VT Ventricular tachycardia
Introduction
Myocarditis is a common inflammatory cardiomyopathy pre-
senting with various clinical manifestations and degrees of
severity [1–3]. It remains one of the most important causes
of dilated cardiomyopathy (DCM) with up to 30% of cases
progressing to DCM [4]. Furthermore, myocarditis is one of
the most common causes of sudden cardiac death in young
adults [5]. Its etiology is often viral or autoimmune [1, 3]. As
of today, accurate diagnosis of myocarditis and identification
of individuals at highest risk for adverse cardiovascular events
remain a challenge [6]. While endomyocardial biopsy (EMB)
is the gold standard for definitive diagnosis of myocarditis [1],
the risk of complications and potential sampling error led to its
use primarily in a selected group of patients as outlined per
AHA/ACC guidelines [2, 7, 8]. Cardiac magnetic resonance
imaging (CMR) is a valuable non-invasive alternative if EMB
is not indicated [9–15]. Furthermore, late gadolinium en-
hancement (LGE) on CMR has been shown to predict poor
outcomes [15–17]. Two recent studies reported that the local-
ization of LGE predicts the degree of severity of adverse car-
diovascular outcomes [17, 18]. Thus, there is a major need for
accurate and practical diagnostic screening tests to identify
high-risk patients with acute myocarditis and refer them to
CMR for assessment of LGE. Circulating cardiac and inflam-
matory markers are routinely obtained from patients with
acute myocarditis with TnT-hs being the gold standard [1, 2,
19]. However, it is uncertain if these markers reflect disease
severity [1, 3, 6, 20–22]. In this study, we sought to test the
hypothesis that the extent of acute myocarditis, measured by




This is a single-center retrospective chart review of all patients
who presented to the University Hospital of Zurich with
suspected acute myocarditis from January 2011 through
December 2017. The local Ethics Committee of the Kanton
of Zurich approved the study protocol.
The patient population consisted of a myocarditis group
and a control group:
1. Myocarditis cohort
This cohort included patients diagnosed with myocarditis
from January 2011 through March 2017. Myocarditis was
diagnosed based on clinical presentation, elevation of TnT-
hs [1, 2] and CMR, after exclusion of obstructive coronary
artery disease through coronary angiography. Coronary angi-
ography was primarily performed by cardiac catheterization or
computed tomography if pretest probability for coronary ar-
tery disease was very low. Forty-four out of eighty-four myo-
carditis patients diagnosed with acute myocarditis met inclu-
sion criteria for the study. To create a homogenous cohort that
only reflects acute myocarditis, the analysis was restricted to
patients with recent symptom onset (≤ 10 days) and patients
with myositis were excluded from the study.
Symptom onset was defined by the occurrence of at least
one of the following complaints: chest pain, dyspnea, new
onset or worsening heart failure, severe arrhythmias, syncope
or cardiac arrest. The primary cohort served to test the corre-
lation of cardiac and inflammatory markers with LGE.
Subsequently, receiver operating curve (ROC) analysis was
performed to identify if the marker with the strongest correla-
tion to LGE can be used for diagnostic screening to identify
patients with myocarditis and to test its diagnostic accuracy.
2. Control group
The second cohort consisted of 22 patients with similar
signs and symptoms as the primary cohort, including eleva-
tion of TnT-hs. Patients with obstructive coronary artery dis-
ease were not included in the control group, and myocarditis
was not supported by CMR. Therefore, they were classified as
myocardial infarction with non-obstructive coronary arteries
(MINOCA). The control group was primarily used to test the
accuracy of the biomarker in distinguishing patients with
myocarditis and LGE on CMR from MINOCA.
Patients Excluded
A total of 15 patients had missing data and one patient with-
drew consent. Twenty-four patients were excluded due to
chronic or recurrent myocarditis, symptoms > 10 days, and/
or known myositis.
Clinical Laboratory Parameters
Blood parameters were analyzed on the day of admission:
high-sensitivity troponin T (TnT-hs), creatine kinase (CK),
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myoglobin, NT-pro brain natriuretic peptide (NT-proBNP), C-
reactive protein (CRP), leukocytes and thrombocytes. Values
for TnT-hs, CK, myoglobin, and CRP were obtained 3, 6, 12,
24, 48, and 72 h after admission.
CMR Examination
CMR imaging was obtained within 10 days after symptom
onset. Images of CMR were performed on a 1.5- or 3.0-
Tesla scanner (SiemensSkyra, Erlangen, Germany or Philips
A c h i e v a , B e s t , T h e N e t h e r l a n d s ) u s i n g a n
electrocardiography-gated breath-hold protocol. Diagnosis
was based on cine-CMR, T2-weighted imaging, and T1-
weighted LGE imaging. For details on CMR examination,
please see supplement.
Clinical Follow-Up
Patients presented for 3 and 6months follow-up, at which time
they were assessed for major adverse cardiovascular events
(MACE) such as malignant arrhythmias, severe chest pain or
dyspnea episodes, new onset heart failure, cardiovascular
death, and all cause-mortality. During physical examination,
the set of circulating cardiac and inflammatory markers were
obtained as outlined above. All patients underwent 12-lead
ECG, 48-h Holter monitoring, and exercise stress testing with
ramp protocol.
Validation of Findings in a Clinically Translatable
Mouse Model of Coxsackievirus B3 Induced
Myocarditis
Male and female BALB/c (6 to 8 weeks old) mice were ob-
tained from the Jackson Laboratory (Bar Harbor, ME) fed
standard chow and housed with corn cobb bedding in animal
rooms where temperature was monitored. Mice were main-
tained under pathogen-free conditions in the animal facility
at Mayo Clinic. Approval was obtained from the Animal
Care and Use Committee of Mayo Clinic for all procedures.
Mice were inoculated intraperitoneally (ip) with 103 plaque
forming units of a heart-passaged stock of CVB3 diluted in
saline or saline alone (controls) on day 0 and myocarditis
examined at day 10 post infection (pi), according to prior
studies [23]. Knowledge of which mice were infected with
CVB3 vs. saline controls were necessary so that samples
could be handled safely by the researcher because CVB3 is
a BSL2 pathogen. Mice were randomly assigned to groups
using simple randomization. Myocarditis was assessed histo-
logically as the percentage of the heart section with inflamma-
tion compared to the overall size of the heart section, as pre-
viously (Fairweather 2014, Coronado 2019). Analysis of sam-
ples was blinded to the researcher using a code. No deaths of
mice occurred in any of the experiments reported in this
manuscript. Sera samples, collected on day 10pi, from indi-
vidual uninfected or CVB3 exposed male and female mice
were used to measure myoglobin (catalog no. MYO-1) and
ultrasensitive troponin (catalog no. CTNI-1-US) using Life
Diagnostic Inc. ELISA kits (West Chester, PA) according to
the manufacturer’s instructions and expressed as ng/mL.
Statistical Analysis
Clinical data are reported as mean ± standard deviation or
median interquartile range (IQR). Animal data are expressed
as mean ± standard error of the mean or as Pearson correlation
coefficient (rp). Correlation between clinical laboratory pa-
rameters and percentage of LGE of left ventricular myocardial
volume on CMR imaging was analyzed using Spearman rank
correlation coefficient (rs). p < 0.05 was considered statistical-
ly significant based on a two-tailed probability. Patients with
myocarditis and LGE > 10% were included in the primary
cohort, in which correlation analysis and development of the
biomarker was performed [17]. Please find details on statisti-
cal analysis in the supplement.
Results
Patient Characteristics
Forty-four patients diagnosed with acute myocarditis during
the years 2011–2017 met inclusion criteria for the study.
Twenty-two patients with myocardial infarction with non-
obstructive coronary arteries (MINOCA), in whom CMR ex-
cluded myocarditis, served as the control group.
Among patients with acute myocarditis, 82% were men
with a mean age of 42 ± 17 years. Twenty-five percent were
smokers, 11% suffered from concomitant coronary artery dis-
ease, 20% from arterial hypertension, and 5% from type II
diabetes. Baseline LVEF was 54 ± 12% based on CMR data.
The mean body mass index (BMI) in patients with myocardi-
tis was 27 ± 4 kg/m2. In the control group, 86% were male
with a mean age of 43 ± 16 years and 32%were smokers. Two
patients (9%) had concomitant coronary artery disease, 18%
arterial hypertension, and 5% were diabetics. The mean BMI
of controls was 26 ± 5 kg/m2 and baseline LVEF was 53 ±
14% based on CMR.
Baseline characteristics of the primary cohort were overall
similar between myocarditis (n = 44) and controls (n = 22,
Table 1). However, TnT-hs and myoglobin levels were higher
in patients with myocarditis compared to controls. While the
mean TnT-hs was 492 ± 645 ng/L in myocarditis, it was 22 ±
18 ng/L in controls (p = 0.03). Mean myoglobin levels were
77 ± 75 μg/L in myocarditis and 24 ± 14 μg/L in controls (p =
0.03). Among 44 patients with myocarditis, there were 18
patients in whom both levels of myoglobin as well as TnT-
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hs were elevated. In patients with elevation of myoglobin and
TnT-hs, there was 16 LGE% of left ventricular volume vs 4
LGE % of left ventricular volume in the group without eleva-
tion of both makers. In addition, CK levels were elevated in
myocarditis compared to controls (290 ± 219 U/L vs 116 ±
74 U/L; p = 0.01).
At presentation, 36 patients (82%) complained of chest
pain, whereas dyspnea was the leading symptom in eight pa-
tients (18%). Additional symptoms were acute decompensat-
ed heart failure in three (7%), palpitations in four (9%), and
syncope in two patients (5%). ECG revealed ST segment ele-
vation in 12 (27%) and STsegment depression in four patients
(9%).
Reproducibility of CMR Interpretation
As previously described by our group [24], intrareader repro-
ducibility for interpretation of CMR data was excellent (r2 =
0.97 in linear regression; p = 0.59 in Bland-Altman). There
was also a strong correlation between CMR interpretation
results between the two readers (r2 = 0.99). In addition, no
proportional bias (p = 0.82) was observed between the two
readers based on Bland Altman analysis.
Correlation Between Laboratory Blood Parameters
and LGE on CMR in Acute Myocarditis
CMR imaging data for individual patients are illustrated in the
supplement (Table S1). Median values and ranges of the
analyzed laboratory parameters for the entire primary cohort
are displayed in Table 2. Strong and significant correlation
was found between myoglobin and LGE (rs = 0.73 [95% CI
0.51; 0.87], p < 0.001, Fig. 1). There were weak to moderate
correlations between LGE and CK (rs = 0.55 [95% CI 0.28;
0.75], p < 0.001), TnT-hs (rs = 0.37 [95% CI 0.09; 0.61], p =
0.01), and CRP (rs = 0.29 [95%CI -0.02; 0.57], p = 0.06) (Fig.
1). There was also a weak correlation between LGE and NT-
proBNP (rs = 0.34 [95% CI 0.03; 0.59], p = 0.04) and Lc (rs =
0.23 [95% CI − 0.05; 0.49], p = 0.13), and no correlation was
found between LGE and Tc (rs = 0.12 [95% CI − 0.18; 0.39],
p = 0.46). Mean baseline levels of myoglobin at symptom
onset were 77 ± 75 μg/L in myocarditis vs. 24 ± 14 μg/L in
controls (p = 0.03). Additional baseline parameters are
displayed in Table 1.
Furthermore, we sought to evaluate if myoglobin and
LGE correlated with LVEF, since it appeared plausible
that an increased extent of LGE would affect left ventric-
ular systolic function. Correlations between myoglobin
and LVEF (rs = − 0.30 [95% CI − 0.55; 0.01], p = 0.05),
as well as LGE and LVEF (rs = − 0.29 [95% CI -0.56;
0.01], p = 0.06) were weak and did not reach statistical
significance.
Myoglobin and Troponin as Predictors of LGE on CMR
in Acute Myocarditis
As we found a strong correlation between myoglobin and
LGE, we sought to determine the optimal cutoff for serum
Table 1 Baseline characteristics of patients with acute myocarditis vs. controls
Characteristics Acute Myocarditis (n = 44) Controls (n = 22) p value
Mean age, (SD) 42 (17) 43 (16) 0.90
Male sex, n (%) 36 (82) 19 (86) 0.74
BMI, mean, (SD) 27 (4) 26 (5) 0.65
Smoker, n (%) 11 (25) 7 (32) 0.77
CAD, n (%) 5 (11) 2 (9) 1
aHTN, n (%) 9 (20) 4 (18) 1
DM, n (%) 2 (5) 1 (5) 1
LVEF, %, (SD) 54 (12) 53 (14) 0.76
TnT-hs, ng/L, (SD) 492 (645) 22 (18) 0.03*
CK, U/L, (SD) 290 (219) 116 (74) 0.01*
Mb, μg/L, (SD) 77 (75) 24 (14) 0.03*
NT-proBNP, ng/L, (SD) 1299 (3105) 291 (288) 0.34
CRP, mg/L, (SD) 30 (38) 13 (20) 0.14
Lc, G/L, (SD) 8 (3) 7 (3) 0.09
Tc, G/L, (SD) 247 (86) 231 (88) 0.59
aHTN arterial hypertension, BMI body mass index, CAD coronary artery disease, CK creatine kinase, CRP C-reactive protein, DM diabetes mellitus, Lc
leukocytes, LVEF left ventricular ejection fraction, Mb myoglobin, NT-pro BNP NT-pro brain natriuretic peptide, SD standard deviation, Tc thrombo-
cytes, TnT-hs high sensitivity troponin T
*p value < 0.05
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myoglobin to detect acute myocarditis on CMR. ROC analy-
sis revealed myoglobin ≥ 87 μg/L to be the optimal cut off
(area under the curve, AUC = 0.88 [95% CI 0.72; 0.97],
Fig. 2a) with 92% sensitivity, 80% specificity, and 85%
accuracy.
We also performed ROC analysis for TnT-hs, the lab-
oratory “gold standard method” to detect myocarditis clin-
ically, in order to test if an optimized cutoff could be
developed and to compare it to the standard reference
range that is currently used in clinical practice. For TnT-
hs, an optimized cutoff value of 201 ng/L was determined
through ROC analysis, which resulted in 77% sensitivity,
48% specificity, and AUC = 0.60 (Fig. 2b). In addition,
we tested the diagnostic accuracy of the clinical reference
range of TnT-hs [0–14 ng/L] which resulted in 100% sen-
sitivity, 22% specificity, and 59% accuracy.
a b
c d
Fig. 1 Correlation of circulating cardiac and inflammatory markers with late gadolinium enhancement (LGE) in acute myocarditis: LGE as % of left
ventricular myocardial volume is illustrated on the x-axis. Levels of a high-sensitivity troponin T (TnT-hs), b creatine kinase (CK), c myoglobin (Mb),
and d C-reactive protein (CRP) are demonstrated on the y-axis. rs = Spearman rank correlation coefficient
Table 2 Correlation between laboratory markers and LGE in acute myocarditis (n = 44)
Laboratory marker Reference range in laboratory Median (IQR) at baseline Correlation with LGE at baseline
TnT-hs (ng/L) < 14 267 (31–682) rs = 0.37 [95% CI: 0.09; 0.61], p = 0.01
CK (U/L) < 190 220 (129–436) rs = 0.55 [95% CI: 0.28; 0.75], p < 0.001
Mb (μg/L) 28–72 43 (30–111) rs = 0.73 [95% CI: 0.51; 0.87], p < 0.001
NT-pro BNP (ng/L) < 85.5 441 (70–951) rs = 0.34 [95% CI: 0.03; 0.59], p = 0.04
CRP (mg/L) < 5 14 (2–43) rs = 0.29 [95% CI: −0.02; 0.57], p = 0.06
Lc (G/L) 3–9.6 8 (6–10) rs = 0.23 [95% CI: −0.05; 0.49], p = 0.13
Tc (G/L) 150–360 223 (196–267) rs = 0.12 [95% CI: −0.18; 0.39], p = 0.46
CK creatine kinase,CRPC-reactive protein, IQR interquartile range, Lc leukocytes, LGE late gadolinium enhancement,Mbmyoglobin,NT-pro BNPNT-
pro brain natriuretic peptide, Tc thrombocytes, TnT-hs high sensitivity troponin T
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Time Course of Laboratory Blood Parameters
The time course of cardiac markers and CRP after admission
with myocarditis is illustrated in Fig. 3a. Mean TnT-hs peaked
at 12 h (mean: 831 ± 822 ng/L) and continued to be elevated
for at least 72 h. Mean CK peaked at 12 h (mean 384 ± 306 U/
L) and normalized 48 h post admission. Mean myoglobin
levels peaked on admission (mean 77 ± 75 μg/L) and normal-
ized on average 3 h later (Fig. 3b). Twenty-four hours post
admission, myoglobin levels had normalized in all patients.
Mean CRP peaked after 12 h (75 ± 77 mg/L) and was still
detectable 72 h later (mean 20 ± 27 mg/L).
Major Adverse Cardiovascular Events in Patients
with Acute Myocarditis
MACE occurred in four patients over a period of 6 months. At
3 months follow-up, two patients with myocarditis underwent
implantation of an intracardiac device. One patient underwent
implantation of a cardioverter defibrillator (ICD) for ventric-
ular fibrillation. Another patient received an implantable
cardiac resynchronization therapy pacemaker (CRT-P) for per-
sistent symptomatic second-degree atrioventricular block. At
6 months follow-up, two patients underwent insertion of an
ICD for symptomatic ventricular tachycardia (VT) with syn-
cope. Among the four patients, three were men (75%). The
average age in men was 43 ± 14 years, while the woman was
43 years old. Myoglobin levels were elevated above the ref-
erence value of 72μg/L at baseline in three of the four patients
with MACE (myoglobin mean level 124 ± 106 μg/L), while
the mean was 73 ± 71 μg/L in patients without MACE (p =
0.20). Three out of the four patients with MACE had elevated
levels of both myoglobin and TnT-hs. No MACE were ob-
served in the control group, who had a mean myoglobin level
of 24 ± 14 μg/L.
Reproducibility of Results in a Clinically Translational
Model of Coxsackievirus B3 Myocarditis
Since patients in our cohort were diagnosed with myocarditis
based on clinical presentation (i.e., elevation of TnT-hs [1, 2]
and CMR after exclusion of obstructive coronary artery disease
through coronary angiography, without a definitive tissue diag-
nosis), we sought to validate our findings in a clinically trans-
lational mouse model of coxsackievirus B3 (CVB3) myocardi-
tis that closely resembles the time-course and pathogenesis of
myocarditis is humans [25, 26]. After intraperitoneal injection
with heart-passaged CVB3 [23, 27], male and female mice
developed acute myocarditis at day 10 post infection.
Myocarditis was confirmed based on histology after the mice
developed myocarditis. Ten mice received a saline control in-
jection, were not infected, and served as controls.
Similar to findings in the human cohort, average myoglo-
bin levels were higher in mice with myocarditis (1468.8 ng/
mL) vs. controls (1032.3 ng/L; p = 0.02). There was no differ-
ence in average TnT-hs levels between mice with myocarditis
vs. controls (3.05 ng/L vs 3.31 ng/L; p = 0.76, Fig. 4). There
was moderate correlation between blood levels of TnT-hs and
myoglobin (rp = 0.48, R
2 = 0.41, p = 0.007, Fig. 5). Similar to
the human cohort, we performed ROC analysis in data obtain-
ed frommice to determine accuracy of myoglobin and TnT-hs
for detecting acute myocarditis. Using the cutoff for myoglo-
bin of 1139.2 ng/mL resulted in 70% accuracy for the detec-
tion of myocarditis, AUC = 0.68, 65% sensitivity, and 80%
specificity (Fig. 6a). For TnT-hs, ROC analysis suggested an
optimal cutoff value of 2.0 ng/L resulting in 43% accuracy,
AUC = 0.68, 50% sensitivity, and 30% specificity.
Discussion
This is the first study to demonstrate a strong correlation of
myoglobin with LGE on CMR in patients with acute myocar-
ditis and to suggest a robust cutoff value for myoglobin to
Fig. 2 Receiver operating curve analysis to obtain optimal cutoffs for
myoglobin (panel a) and high sensitivity troponin T (panel b) to
identify patients with acute myocarditis and LGE on CMR
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predict LGE on CMR. The data are biologically plausible, as
circulating cardiac markers such as myoglobin are frequently
released during acute injury of cardiomyocytes [28, 29].
While myoglobin and CK had been used to diagnose acute
coronary syndrome (ACS) in the past, cardiac troponin is now
the standard of care during the last decade due its higher spec-
ificity [30, 31]. As in ACS, troponin is currently considered to
be the most sensitive biomarker to detect myocarditis in those
with non-obstructive coronary artery disease [32]. However,
normal troponin levels do not exclude myocarditis [1, 6].
Myoglobin is an oxygen binding protein, which is typ-
ically released within 3 h of myocardial injury [33–36]
followed by an elimination half-time of 5.2 min [37]. A
study in myoglobin-knockout mice suggested that myo-
globin plays an important role in oxygen delivery to mi-
tochondria [38]. Horike and colleagues analyzed the de-
gree of myoglobin staining in EMBs of patients with
myocarditis using immunohistochemistry and found that
myoglobin staining relates to disease severity as well as
the duration of acute myocarditis [39]. Their findings are
in agreement with our data suggesting higher levels of
myoglobin are associated with worse disease. Since myo-
carditis typically presents as a systemic illness that may
also affect skeletal muscle [40, 41], it is plausible that
more severe acute myocarditis may be associated with
the release of myoglobin from skeletal muscle, which
could contribute to higher blood levels of the marker.
Our data suggest that myoglobin strongly correlates with
LGE on CMR adding value as a laboratory marker to estimate
disease extent. A cutoff value of 87 μg/L for myoglobin per-
formed with 92% sensitivity, 80% specificity, and 85% accura-
cy in identifying patients with myocarditis and LGE on CMR.
While sensitivity and specificity of myoglobin for myocar-
ditis appears to be superior to TnT-hs in the setting of myocar-
ditis, studies that examined other forms of cardiac injury, e.g. in
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Fig. 3 Time course of cardiac and inflammatory markers during acute
myocarditis: Time points of blood collection are illustrated on the x-axis.
Mean levels of the examined blood parameters are demonstrated on the y-
axis. Standard deviation is indicated in panel a. Panel b shows mean
levels of myoglobin at given time points. The dotted red line indicates
the upper reference value of myoglobin. CK, creatine kinase; CRP, C-
reactive protein; Mb, myoglobin; TnT-hs, high sensitivity troponin T
Fig. 4 Myoglobin and high sensitivity troponin T (TnT-hs) blood levels
in mice infected with heart-passaged CVB3 vs. saline controls. The panel
on the left depicts myoglobin blood levels of controls (bar with diagonal
stripes, n = 10 mice) and of mice with myocarditis during acute myocar-
ditis at day 10 post infection (bar in solid black, n = 16 mice). Myoglobin
was significantly elevated in myocarditis (p = 0.02). The panel on the
right depicts blood levels of TnT-hs of controls (bar with diagonal stripes)
and of mice with myocarditis (bar in solid black). There was no signifi-
cant difference in TnT-hs blood levels between mice with myocarditis vs.
controls. Data show the mean ± SEM. Significance determined using
Student’s t test
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identified TnT-hs to be the marker with the highest specificity
and sensitivity, whereas myoglobin performed weakly [42, 43].
These data suggest that myoglobin is not only a valuable
qualitative, but also quantitative marker for LGE in patients
with myocarditis. As LGE was recently identified as a strong
predictor of adverse cardiovascular outcomes [15–17], our
findings suggest that myoglobin may aid in assessing risk
when CMR is not immediately accessible. In line with these
findings, patients with myocarditis and MACE were found to
have significantly higher myoglobin levels compared to con-
trols. A time course analysis of cardiac and inflammatory
markers in myocarditis revealed peak of myoglobin levels
upon admission and normalization 3 h later (Fig. 3).
Therefore, it is critical that myoglobin serum levels are deter-
mined early in patients with suspected myocarditis.
Myoglobin is easily accessible for analysis as a routine blood
test and is available in most clinical settings at low cost (ap-
proximately 30 Euros or 58 USD/sample). Furthermore, the
ability to obtain results within 1 h makes myoglobin an excel-
lent screening tool for myocarditis. This is clinically relevant,
as myocarditis continues to be underdiagnosed due to an often
limited accessibility to CMR at some sites and a high thresh-
old for EMB given its risk for complications [7]. Early recog-
nition of myocarditis is critical for accurate diagnosis and
appropriate treatment and to improve our understanding of
the disease. Surprisingly, correlation of TnT-hs and CK with
LGE were only weak for patients with myocarditis in this
study, but aligns with a recently published study analyzing
the correlation of LGE with TnT-hs and CK, but not with
myoglobin in patients with suspected myocarditis [44].
Importantly, we tested the newly developed cutoff for
serum myoglobin with TnT-hs, the current laboratory gold
standard for the diagnosis of myocarditis. First, we ap-
plied ROC analysis to investigate an optimal cutoff for
TnT-hs to identify patients with myocarditis and LGE.
Using an optimized cutoff of 201 ng/L, diagnostic sensi-
tivity of TnT-hs was 77% with only 48% specificity, and
AUC = 0.60. Without prior optimization of the cutoff and
applying the standard reference range of TnT-hs [0–14 ng/
L], specificity decreased further to 22%.
Finally, we reproduced our findings in a clinically transla-
tional mouse model of CVB3 myocarditis that uses heart-
passaged virus to induce disease. While elevated myoglobin
levels detected myocarditis in mice with 70% accuracy, diag-
nostic accuracy for TnT-hs was only 43%.
Fig. 6 Receiver operating curve analysis to obtain optimal cutoffs for
myoglobin (panel a) and high sensitivity troponin T (panel b) to assess
diagnostic accuracy of these markers in mice with acute CVB3
myocarditis
Fig. 5 Correlation between high
sensitivity troponin T and
myoglobin in sera frommice with
CVB3 myocarditis at day 10 post
infection (rp = 0.48 R
2 = 0.41, p =
0.007). rp = Pearson’s correlation
coefficient. n = 26 mice
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In summary, our data suggest that serum myoglobin is a
valuable screening tool to identify patients with myocarditis
and LGE on CMR as it peaks early, reflects acuity due to its
short lifespan, and appears to perform more accurately in acute
myocarditis than the current laboratory gold standard TnT-hs.
The data are biologically plausible, as myoglobin is released
during cardiac injury [28, 29, 45] and its expression on EMBs
increases with the severity of myocarditis [39]. Our findings on
myoglobin obtained from the human myocarditis cohort
reproduced in a clinically relevant mouse model of CVB3 myo-
carditis. Our data further suggest that myoglobin provides qual-
itative, quantitative, and prognostic information with strong cor-
relation to LGE—a risk predictor of MACE. Availability of
serummyoglobin as a routine blood test in most clinical settings
for low cost and the ability to obtain results within 1 h make it a
potentially valuable diagnostic tool for broad screening and clin-
ical decision making to triage patients for CMR.
We show for the first time that serum myoglobin strongly
correlates with LGE on CMR in acute myocarditis and that
myoglobin may serve as a surrogate for severe myocardial dam-
age in patients withmyocarditis. Sincemyoglobin is available in
most emergency rooms as a routine laboratory test, it may add
value in guiding triage for CMR. This could be particularly
helpful in hospitals without a CMR infrastructure where patients
are transferred to a tertiary care center for further imaging.
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